Plain-English translation of NCT07223814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called , when added to standard chemotherapy, helps treat acute myeloid leukemia (AML) — a serious blood cancer — in patients whose cancer cells have specific genetic changes (in the NPM1 or KMT2A genes). All participants will receive standard chemotherapy, but some will also receive while others receive a placebo (a fake pill), so researchers can compare how well the medication works. Neither you nor your doctor will know which treatment you're receiving until the trial ends.
Current treatments for this type of blood cancer don't work well enough for all patients, and doctors are looking for ways to improve survival and outcomes. This medication works by stopping a specific process in cancer cells that have these genetic changes, and researchers believe it could make chemotherapy more effective.
You likely qualify if…
You likely don't qualify if…
You will receive standard chemotherapy treatment over several months (induction and consolidation phases), combined with either or placebo pills. After the initial chemotherapy phases end, you will continue taking either or placebo as maintenance therapy for as long as the treatment is working and you tolerate it well. You will have regular clinic visits for blood tests, physical exams, and monitoring. The trial also includes a 4-year follow-up period after the last patient is enrolled, during which researchers will track how you are doing.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States